Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia by Rana, Sarosh et al.
 
Plasma Concentrations of Soluble Endoglin versus Standard
Evaluation in Patients with Suspected Preeclampsia
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Rana, Sarosh, Ana Sofia Cerdeira, Julia Wenger, Saira Salahuddin,
Kee-Hak Lim, Steven J. Ralston, Ravi I. Thadhani, and S. Ananth
Karumanchi. 2012. Plasma concentrations of soluble endoglin
versus standard evaluation in patients with suspected
preeclampsia. PLoS ONE 7(10): e48259.
Published Version doi:10.1371/journal.pone.0048259
Accessed February 19, 2015 11:51:05 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10510853
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAPlasma Concentrations of Soluble Endoglin versus
Standard Evaluation in Patients with Suspected
Preeclampsia
Sarosh Rana
1,2*, Ana Sofia Cerdeira
3,4, Julia Wenger
5, Saira Salahuddin
2, Kee-Hak Lim
2,6,
Steven J. Ralston
1,2, Ravi I. Thadhani
5, S. Ananth Karumanchi
1,2,3,7
1Division of Maternal Fetal Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America, 2Department
of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America, 3Department of
Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America, 4Gulbenkian Programme for Advanced
Medical Education, Lisbon, Portugal, 5Division of Nephrology/Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston,
Massachusetts, United States of America, 6Boston Maternal Fetal Medicine Group, Boston, Massachusetts, United States of America, 7Howard Hughes Medical Institute,
Chevy Chase, Maryland, United States of America
Abstract
Background: The purpose of this study was to compare plasma soluble endoglin (sEng) levels with standard clinical
evaluation or plasma levels of other angiogenic proteins [soluble fms-like tyrosine kinase 1 (sFlt1) and placental growth
factor (PlGF)] in predicting short-term adverse maternal and perinatal outcomes in women with suspected preeclampsia
presenting prior to 34 weeks.
Methods and Findings: Data from all women presenting at ,34 weeks for evaluation of preeclampsia with singleton
pregnancies (July 20092October 2010) were included in this analysis and sEng levels were measured at presentation. Data
was analyzed for 170 triage encounters and presented as median {25275
th centile}. Thirty-three percent of patients (56 of
170) experienced an adverse outcome. sEng levels (ng/ml) were significantly elevated in patients who subsequently
experienced adverse outcomes compared to those who did not (32.3 {18.1, 55.8} vs 4.8 {3.2, 8.6}, p,0.0001). At a 10% false
positive rate, sEng had higher detection rates of adverse outcomes than the combination of highest systolic blood pressure,
proteinuria and abnormal laboratory tests (80.4 {70.0, 90.8} vs 63.8 {51.4, 76.2}, respectively). Subjects in the highest quartile
of sEng were more likely to deliver early compared to those in the lowest quartile (HR: 14.96 95% CI: 8.73225.62, p,0.0001).
Natural log transformed sEng correlated positively with log sFlt1 levels (r=0.87) and inversely with log PlGF levels
(r=20.79) (p,0.0001 for both). Plasma sEng had comparable area under the curve for prediction of adverse outcomes as
measurement of sFlt1/PlGF ratio (0.88 {0.81, 0.95} for sEng versus 0.89 {0.83, 0.95} for sFlt1/PlGF ratio, p=0.74).
Conclusions: In women with suspected preeclampsia presenting prior to 34 weeks of gestation, sEng performs better than
standard clinical evaluation in detecting adverse maternal and fetal outcomes occurring within two weeks of presentation.
Soluble endoglin was strongly correlated with sFlt1 and PlGF levels, suggesting common pathogenic pathways leading to
preeclampsia.
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Introduction
Preeclampsia is a common complication of pregnancy affecting
528% of all pregnant women. A clinical diagnosis of preeclampsia
is traditionally defined as development of new onset hypertension
and proteinuria after 20 weeks of gestation [1]. The current
practice for management of patients with a suspicion for
preeclampsia involves admission to the hospital for follow-up
and management of elevated blood pressures, assessment of 24-
hour urine for proteinuria and various blood tests for the
evaluation of end-organ damage [2]. In women carrying preterm
fetuses, prolongation of pregnancy is of clear benefit, but this is
often dangerous to the pregnant woman herself for whom delivery
is the only cure; balancing the needs of the fetus and the needs of
the pregnant woman, therefore, becomes a significant clinical
challenge. Accurate risk stratification is therefore critical in women
with preterm preeclampsia for the appropriate management.
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with atypical signs and symptoms, risk stratification is important to
allow for appropriate downstream testing and follow-up. Patients
deemed at high risk for developing an adverse outcome need to be
hospitalized often with transfer to a tertiary center for an
anticipated preterm delivery, given betamethasone to promote
fetal lung maturity, and monitored closely for maternal and fetal
status to appropriately time delivery. Conversely, iatrogenic
preterm delivery needs to be avoided in women at low risk of
adverse outcomes.
Clinical studies have shown that it is challenging to predict
adverse outcomes in women with a suspicion of preeclampsia
[3,4,5]. In a recent study, von Dadelszen and colleagues used
various clinical parameters in patients admitted with a diagnosis of
preeclampsia to compute the risk of developing adverse outcome.
Their final model included gestational age, serum creatinine,
platelet count, aspartate aminotransferase, oxygen saturation and
chest pain or dyspnea. The area under curve (AUC) for the
prediction of adverse maternal outcomes within 48 hours of study
eligibility was 0.88 (95%CI 0.8420.92) and up to 7 days was .0.7
[6].
Data from our laboratory and others have shown that
angiogenic factors are altered in women with preeclampsia at
the time of clinical diagnosis and weeks to months before the
clinical onset of disease [7]. It has been shown that levels of soluble
fms-like tyrosine kinase (sFlt1) and soluble endoglin (sEng) are
elevated while placental growth factor (PlGF) are reduced in
women with diagnosis of preeclampsia and these levels correlate
with disease severity and gestational age [8,9,10,11]. The
availability of automated assays for sFlt1 and PlGF, has enabled
researchers to determine the clinical utility of these markers in the
diagnosis and management of preeclampsia [12,13,14,15,16].
While there are number of clinical studies evaluating the role of
sFlt1 and PlGF in preeclampsia, there is a paucity of data
Table 1. Characteristics of all Subjects and Stratified by Adverse Outcome Status.
Variable All patients No Adverse Outcomes Adverse Outcomes p-value
N 170 114 56
Baseline
Gestational Age (weeks) 31.1 (28.1, 32.9) 30.9 (28.1, 32.9) 31.9 (28.3, 32.9) 0.60
Age (years) 32 (27, 36) 32 (28, 36) 31 (27, 36) 0.37
Body Mass Index (kg/m
2) 33.0 (29.2, 38.5) 33.7 (30.3, 38.5) 30.8 (28.0, 38.6) 0.13
Nulliparous (%) 55.9 (95) 55.3 (63) 57.1 (32) 0.82
Smoker (%) 8.2 (14) 7.9 (9) 8.9 (5) 0.82
Race 0.50
White/Caucasian 56.5 (96) 54.4 (62) 60.7 (34)
Black/African American 20.6 (35) 21.1 (24) 19.6 (11)
Asian 5.9 (10) 5.3 (6) 7.1 (4)
Other 17.0 (29) 19.3 (22) 12.5 (7)
History of Preeclampsia 21.2 (36) 21.1 (24) 21.4 (12) 0.96
History of Chronic Hypertension 31.8 (54) 33.3 (38) 28.6 (16) 0.53
History of Diabetes 10.0 (17) 11.4 (13) 7.1 (4) 0.38
Presentation
Highest SBP in Triage (mmHg) 140 (130, 150) 135 (124, 144) 149 (141, 160) ,0.0001*
Highest DBP in Triage (mmHg) 87 (77, 96) 84 (74, 92) 96 (86, 103) ,0.0001*
Proteinuria (%, N) 35.3 (60) 19.3 (22) 67.9 (38) ,0.0001*
ALT in Triage (U/L) 17 (12, 27) 16 (12, 23) 20 (13, 40) 0.01*
Creatinine in Triage (mmol/L) 53.0 (44.2, 61.9) 44.2 (44.2, 53.0) 61.9 (44.2, 70.7) 0.0001*
Uric Acid in Triage (mmol/L) 261.7 (220.1,339.0) 243.9 (208.2,285.5) 345.0 (273.6,398.5) ,0.0001*
Platelet Count in Triage (10
9/L) 253 (205, 291) 262 (227, 296) 234 (166, 274) 0.002*
Outcomes
Any Hypertensive Disorder
Chronic HTN 24.1 (41) 28.1 (32) 16.1 (9) 0.09
Gestational HTN 17.1 (29) 23.7 (27) 3.6 (2) 0.001*
Preeclampsia 31.8 (54) 8.8 (10) 78.6 (44) ,0.0001*
GA of delivery 35 (32, 37) 37 (35, 38) 32 (28, 33) ,0.0001*
Birth weight 2,550 (1,575, 3,270) 2,958 (2,403, 3,365) 1,460 (850, 1,805) ,0.0001*
SBP= Systolic Blood Pressure, DBP= Diastolic Blood Pressure, ALT= Alanine aminotransaminase, HTN= Hypertension.
Table shows median (quartile 1, quartile 3) or % (n) where appropriate.
Subjects without a populated endoglin value were eliminated from the current analysis.
*Significant at p,0.05 comparing patients with and without adverse outcomes.
To convert creatinine to mg/dL- divide by 88.4. To convert uric acid to mg/dL- divide by 59.48.
doi:10.1371/journal.pone.0048259.t001
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with preeclampsia. sEng has also been previously shown to be
elevated in women with established preeclampsia, especially in
those presenting prematurely and/or in mothers carrying a growth
restricted fetus [10,17,18]. In a cohort of patients presenting to the
obstetrical triage unit prematurely (,34 weeks) that have been
previously evaluated for sFlt1 and PlGF [15], we compared sEng
with that of standard evaluation in the prediction of adverse
maternal and neonatal outcomes occurring within 2 weeks of
presentation. We also explored whether the addition of sEng to
sFlt1/PlGF ratio improves the prediction of adverse outcomes.
Methods
Ethics Statement
The study was approved by the Beth Israel Deaconess Medical
Center Institutional Review Board (IRB), and all patients provided
written informed consent.
Study Population
This is part of an ongoing prospective cohort study on all
pregnant patients who present to obstetrical triage at Beth Israel
Deaconess Medical Center (BIDMC), Boston, MA, as described
elsewhere [15]. These patients were either referred by their
obstetric provider because of signs of preeclampsia or self-
presented with symptoms of preeclampsia. Patients were included
if the triage care provider deemed an evaluation of preeclampsia
necessary. Samples were collected within one hour of arrival to
triage and stored at 280uC for analysis. For this current study, all
singleton women presenting ,34 weeks of gestation and enrolled
between July 20092October 2010 were included, as described
elsewhere [15].
Measurement of soluble endoglin (sEng)
Enzyme-linked immunosorbent assay (ELISA) for sEng was
performed with commercially available kits, as previously
described (R&D systems, Minneapolis, MN). Assays were
performed in duplicate and values averaged. The correlation
Figure 1. sEng levels among women with suspected preeclampsia. A: Distribution of sEng levels at initial presentation according to
diagnosis ascertained at 2 weeks. Median and 25
th275
th percentile for sEng levels at presentation stratified by diagnosis. All diagnoses were
ascertained 2 weeks after presentation. All p values presented on the figure are compared to those without a diagnosis at 2 weeks (‘‘normal’’,
reference). The median (25th, 75
th percentile) of sEng (ng/ml) for each group are as follows: Normal=4.8 (3.5, 7.1), PE=30.2 (12.7, 55.7), gestational
HTN=6.2 (4.5, 14.0), chronic HTN=4.6 (3.0, 9.4). B: Distribution of sEng levels at initial presentation according to adverse outcomes
ascertained at 2 weeks. Median and 25
th275
th percentile for sEng levels at presentation stratified by adverse outcomes. All outcomes were
ascertained 2 weeks after presentation. All p values presented on the figure are compared to those without an adverse outcome at 2 weeks
(‘‘normal’’, reference). The median (25th, 75
th percentile) of sEng (ng/ml) for each group are as follows: No adverse outcome=4.8 (3.2, 8.6), adverse
outcome=32.3 (18.1, 55.8), elevated liver function tests/low platelets=32.9 (21.8, 40.0), small for gestational age (SGA)=69.9 (32.8, 99.0),
abruption=22.2 (21.8, 38.2).
doi:10.1371/journal.pone.0048259.g001
Figure 2. sEng levels and predictive risk of adverse outcome.
The cumulative predicted risk of adverse outcomes at different levels of
sEng. The sample sizes shown below the figure represent the number of
patients at risk for each 20 ng/ml increment of sEng.
doi:10.1371/journal.pone.0048259.g002
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interassay coefficients of variation were 3.0 and 6.3%. Plasma
levels of sFlt1 and PlGF in this same population have been
previously published [15].
Clinical Data
All participants’ charts were reviewed to determine outcomes
within two weeks of their initial preeclampsia evaluation. We
chose a two week interval because previous studies have shown
that the levels of angiogenic factors start to rise five weeks before
clinical disease and peak two weeks prior to the manifestation of
the clinical syndrome [8,19]. All available clinical data were
collected during the two weeks after the initial preeclampsia
evaluation including age, race, height, weight, smoking status,
gestational age at the time of triage visit, clinical findings, blood
pressure (BP), and the results of laboratory tests and fetal scans. All
pregnancy outcomes including complications and delivery char-
acteristics such as route of delivery, birth weight and diagnosis of
hypertensive disorder were recorded.
Primary Outcome
The diagnoses of preeclampsia, gestational hypertension, and
chronic hypertension were based on American College of
Obstetrics and Gynecology (ACOG) criteria with some minor
modifications [1]. Preeclampsia was defined as hypertension (a
blood pressure $140/90 on two occasions 2 hours to 2 weeks
apart) after 20 weeks of gestation and proteinuria of $300 mg/
24 hour or urine protein to creatinine (P/C) ratio of $0.3 after
20 weeks of gestation. Gestational hypertension was defined as the
presence of hypertension as defined above without proteinuria and
chronic hypertension was defined as the presence of hypertension
prior to 20 weeks of gestation. We diagnosed superimposed
preeclampsia in women with chronic hypertension if there was a
significant increase in blood pressure compared with baseline
($30 mm Hg systolic, $15 mm Hg diastolic) in association with
new-onset proteinuria (either 300 mg per 24 hours or urine P/C
ratio of $0.3). If proteinuria was present at baseline, superimposed
preeclampsia was diagnosed if there was doubling of urinary
protein excretion after 20 weeks’ gestation in association with a
significant increase in BP. Superimposed preeclampsia was also
diagnosed if blood pressure was elevated and there were elevated
liver enzymes (two times baseline) or a low platelet count
(#100610
9/L).
Adverse maternal outcomes were defined as the presence of
hypertension as defined above plus one of the following: elevated
liver function test (LFT) including aspartate aminotransferase
(AST) or alanine aminotransferase (ALT) ($80 U/L), thrombo-
cytopenia (platelet count #100610
9/L), disseminated intravascu-
lar coagulation (DIC), abruption (clinical and/or pathological),
pulmonary edema, cerebral hemorrhage, seizure (in a woman
without an underlying seizure disorder), acute renal failure
(creatinine .132.6 mmol/L), or maternal death [20]. The adverse
fetal/neonatal outcomes included iatrogenic delivery indicated for
hypertensive complications of pregnancy as reported by the
primary obstetrician, small for gestational age birth weight (#10
th
percentile for gestational age), abnormal umbilical artery Doppler
(absent or reverse flow), fetal death, and neonatal death [20]. The
presence of adverse outcomes was determined by two study staff
members without knowledge of the assay results. Diagnosis and
adverse outcomes were ascertained within 2 weeks of presentation.
Statistical analysis
Baseline characteristics of patients with and without adverse
outcomes were compared using the Wilcoxon rank sum and chi-
square tests where appropriate. As the distributions of many of the
clinical characteristics were highly skewed, baseline measures are
presented as medians, 25
th275
th percentile. The Wilcoxon rank
sum test was also used to compare levels of sEng by diagnosis and
type of adverse outcome. Pearson correlation coefficients were
used to examine the associations between natural log transformed
Table 2. Detection of Adverse Outcomes in 2 Weeks using various clinical markers and sEng.
FPR Highest BP Highest BP + protein
Highest BP + Protein +
Platelets + ALT + UA Endoglin Highest BP + Protein + Endoglin
2 17.0 (7.4, 26.5) 28.8 (17.3, 40.4) 37.9 (25.4, 50.4) 57.1 (44.2, 70.1) 64.3 (51.7, 76.8)
5 30.5 (18.8, 42.3) 50.9 (38.1, 63.6) 55.2 (42.4, 68.0) 69.6 (57.6, 81.7) 73.2 (61.6, 84.8)
10 32.2 (20.3, 44.1) 61.0 (48.6, 73.5) 63.8 (51.4, 76.2) 80.4 (70.0, 90.8) 76.8 (65.7, 87.8)
FPR= False Positive Rate.
The detection rate is the percentage of those with adverse outcomes in 2 weeks detected with the use of a given marker based on the FPR and its associated odds ratio
cut-off. Confidence intervals were derived from the binomial distribution.
doi:10.1371/journal.pone.0048259.t002
Figure 3. Kaplan-Meier estimates of time to delivery according
to sEng quartiles. Kaplan-Meier survival function for time to delivery
in all participants by quartile of sEng is depicted. Subjects remained in
the analysis until delivery. Univariate Cox Proportional Hazard Models
showed quartiles 3 and 4 of sEng had a significantly higher risk of early
delivery (HR: 3.14, 95% CI: 1.9924.98 and HR: 14.96, 95% CI: 8.73225.62;
both p,0.0001) compared to the lowest quartile. The second quartile
showed no significant differences in time to delivery compared to
quartile 1 (p=0.07).
doi:10.1371/journal.pone.0048259.g003
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correlations were used to examine the relationship between sEng
levels and other baseline factors. Univariate and multivariate
logistic regression analysis were used to evaluate significant
predictors of adverse outcomes as well as to examine the predicted
risk of adverse outcomes at different values of sEng. We computed
the detection rate (the percentage of subjects with adverse
outcomes within 2 weeks of triage by odds ratio cut-offs) at
various false positive rates for sEng as well as various biomarkers.
Confidence intervals for the detection rate were estimated using
the binomial distribution. To determine the clinical utility of sEng
we used receiver operating characteristic (ROC) analysis. To
compare areas under the curve we used sFlt1, PIGF, and the
sFlt1/PlGF ratio as the reference groups as these markers for
adverse outcomes has been established previously. To find the best
predictive value of adverse outcomes for various cut-points of
sEng, we calculated sensitivity, specificity, positive predictive value
(PPV) defined as the proportion of sEng results above the cut-point
that are true positives, and negative predictive value (NPV), the
proportion of sEng results below the cut-point that are true
negatives. Time to delivery by quartiles of sEng levels was
visualized using Kaplan Meier curves and calculated using Cox
Proportional Hazard Models. Delivery within 2 weeks by quartiles
of sEng levels was analyzed using a chi-square test. SAS software,
version 9.2 (SAS Institute), was used for all analyses. Two-tailed p-
values of ,0.05 were considered significant.
Results
Demographic and Clinical Characteristics
Demographics of all patients which are part of the original
cohort are described elsewhere [15]. During the study period, 815
preeclampsia evaluations took place. One hundred seventy-six
evaluations occurred ,34 weeks’ gestation. Of these evaluations, 6
were eliminated due to missing blood samples. Of the remaining
170 evaluations, 18 (10.6%) were repeat evaluations of women
previously enrolled. Baseline characteristics at presentation to
obstetric triage of all women and women who did and did not
experience subsequent adverse outcomes are shown in Table 1.
Over a course of two weeks, adverse outcomes occurred in
32.9% of subjects (N=56). The most common adverse outcome
was indicated delivery (96.4%, N=54). Of those patients with
Figure 4. Correlation between sFlt1 and sEng (panel A) and between PlGF and sEng (Panel B). Variables were natural log transformed
and p-values were derived from Pearson correlation coefficients.
doi:10.1371/journal.pone.0048259.g004
Table 3. Comparison of sEng, PlGF, and sFlt1 among Different Outcomes.
Outcomes sEng PlGF p-value* sFlt1 p-value**
Adverse Outcome 0.88 (0.81, 0.95) 0.87 (0.80, 0.93) 0.55 0.87 (0.80, 0.93) 0.44
Elev LFT/Low PLT 0.82 (0.73, 0.91) 0.81 (0.69, 0.92) 0.61 0.85 (0.74, 0.96) 0.43
SGA 0.93 (0.88, 0.98) 0.92 (0.88, 0.97) 0.75 0.87 (0.79, 0.95) 0.003*
Abruption 0.70 (0.40, 0.99) 0.76 (0.58, 0.94) 0.41 0.80 (0.67, 0.92) 0.37
DIC 0.85 (0.78, 0.93) 0.75 (0.32, 1.00) 0.61 0.88 (0.63, 1.00) 0.89
*Model performs significantly different at p,0.05 comparing sEng to PIGF.
**Model performs significantly different at p,0.05 comparing sEng to sFlt1.
Elev LFT/Low PLT= elevated LFT’s (aspartate aminotransferase and alanine aminotransferase)/ Low platelets.
SGA= small for gestational age, DIC= disseminated intravascular coagulation.
doi:10.1371/journal.pone.0048259.t003
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HELLP syndrome. Patients who had adverse outcome had higher
systolic and diastolic blood pressures (p,0.0001), higher protein-
uria (p,0.0001), higher alanine aminotransferase (p=0.01),
higher uric acid (p,0.0001) and lower platelets (p=0.002) than
women who did not experience an adverse outcome. (Table 1).
sEng and subsequent clinical outcomes
The median (25
th275
th percentile) plasma sEng levels (ng/ml)
were significantly higher in women who developed preeclampsia
(30.2 {12.7, 55.7}) and gestational HTN (6.2 {4.5, 14.0})
compared with women with no hypertensive disorder (4.8 {3.5,
7.1}; p,0.0001, and p=0.04 respectively). The levels were similar
in patients with chronic hypertension and normal pregnancy
outcomes (Figure 1A).
Importantly, levels of plasma sEng (ng/ml) were higher in
women who experienced any adverse outcome compared to
women who did not (32.3 {18.1255.8} vs 4.8 {3.228.6}
p,0.0001). In the subgroup analysis, levels of sEng (ng/ml) were
higher in women with elevated LFT/low platelet (32.9 {21.8,
40.0}), SGA (69.9 {32.8, 99.0}), and abruption (22.2 {21.8, 38.2})
compared to women with no adverse outcomes (4.8 {3.2, 8.6};
p,0.0001 for elevated LFT/low platelet and SGA and p=0.02
for abruption). (Figure 1B).
Predictive accuracy of sEng
In univariate logistic regression models greater sEng, systolic
blood pressure, diastolic blood pressure, proteinuria, uric acid,
creatinine, and lower platelet count were associated with higher
risk of adverse outcomes (p,0.001 for sEng, SBP, DBP,
proteinuria, and uric acid; p=0.008 for creatinine; p=0.006 for
platelet count).
On multivariate analysis (controlling for maternal age, parity,
BMI, and smoking status), only platelet count (p=0.047) and sEng
(p=0.02) remained significantly associated with adverse outcomes.
To evaluate dose response, we calculated the predictive risk of
adverse outcomes by sEng level and noted that higher levels of
sEng were associated with greater risk of adverse outcomes
(Figure 2).
The rates of detection of adverse outcomes using various clinical
markers each at different false positive rates are shown in Table 2.
At each false positive rate, sEng had the highest detection rate
compared to blood pressure, proteinuria, platelet count, alanine
aminotransaminases and uric acid in different combinations. In
addition, hypertension and proteinuria added to sEng did not
substantially improve its detection of adverse events at higher false
positive rates.
We performed receiver operating characteristic (ROC) analysis
and found that AUC for sEng alone was 0.88 (0.81, 0.95) and 0.93
(0.89, 0.97) for sEng combined with blood pressure and
proteinuria (p=0.03). Using a cut-off of 12 ng/ml for sEng a
total of 107 (62.9%) subjects fell at or below the cut-off while 63
(37.1%) were above. This cut-off showed high diagnostic accuracy
for adverse outcomes with a sensitivity of 80.4%, a specificity of
88.6%, a PPV of 77.6%, a NPV of 90.2%, a positive LR of 7.1 and
negative LR of 0.2. Close examination of the false negatives
suggested that 8 of 9 subjects that had adverse outcomes with low
sEng values had no signs of end-organ damage, but had indicated
delivery (Table S1). Among the false positives, 12/16 had
preeclampsia related delivery #37 weeks beyond 2 weeks (average
time between triage evaluation and outcome was 5.2 weeks)
(Table S2). Subjects at or below the cut-off had significantly
higher BMI (p=0.001) and platelet count (p,0.0001) and lower
systolic blood pressure (p,0.0001), ALT (p=0.003), creatinine
(p,0.0001), and uric acid (p,0.0001).
sEng and time to delivery
Kaplan-Meier curves depicting cumulative probability of
remaining undelivered for women in the four quartiles for sEng
levels are shown in Figure 3. The highest sEng levels (4
th quartile)
were associated with shorter time to delivery. The proportion of
patients that delivered within 2 weeks was 90.4% among those
patients with sEng levels in the 4th quartile (highest levels), as
compared to 14.3% among those with sEng levels in the 1st
quartile (lowest levels) (p,0.0001). Those in the highest quartile of
sEng were 15 times more likely to deliver early compared to those
in the lowest quartile (HR: 14.96 95% CI: 8.73225.62, p,0.0001)
This relationship was slightly attenuated but remained significant
after adjustment for gestational age at presentation, highest systolic
blood pressure measured in triage, and proteinuria at presentation
(HR: 8.10 95% CI: 4.49214.64, p,0.0001).
sEng and others angiogenic factors
Natural log transformed levels of sEng were positively correlated
with log sFlt1 (rs=0.87, p,0.0001) and inversely to log PlGF
(rs=20.79, p,0.0001) Figure 4A and 4B. Similarly, levels of
sEng were found to be strongly correlated with timing of delivery,
BP in triage, serum creatinine, and UA (rs20.70, 0.44, 0.34, 0.49
all p,0.0001). sEng showed comparable performance to sFlt1,
PlGF and sFlt1/PlGF for the prediction of adverse outcomes.
Addition of sEng to sFlt1/PlGF ratio did not improve the
sensitivity of the ratio. (Table 3 and 4).
Table 4. Comparison of sFlt1/PlGF and combination of sEng among Different Outcomes.
Outcomes sEng sFlt1/PlGF p-value* sEng+sFlt1/PlGF p-value**
Adverse Outcome 0.88 (0.81, 0.95) 0.89 (0.83, 0.95) 0.74 0.89 (0.83, 0.95) 0.41
Elev LFT/Low PLT 0.82 (0.73, 0.91) 0.85 (0.73, 0.96) 0.33 0.83 (0.72, 0.94) 0.16
SGA 0.93 (0.88, 0.98) 0.91 (0.86, 0.96) 0.26 0.94 (0.90, 0.98) 0.01*
Abruption 0.70 (0.40, 0.99) 0.79 (0.63, 0.94) 0.32 0.76 (0.56, 0.95) 0.37
DIC 0.85 (0.78, 0.93) 0.91 (0.87, 0.96) 0.10 0.87 (0.73, 1.00) 0.51
*Model performs significantly different at p,0.05 comparing sEng to sFlt1/PIGF.
**Model performs significantly different at p,0.05 comparing sFlt1/PIGF to sEng +sFlt1/PlGF.
Elev LFT/Low PLT= elevated LFT’s (aspartate aminotransferase and alanine aminotransferase)/ Low platelets.
SGA= small for gestational age, DIC= disseminated intravascular coagulation.
doi:10.1371/journal.pone.0048259.t004
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In this clinical study, we demonstrate that plasma sEng levels
were associated with adverse maternal and perinatal outcomes
among women presenting to obstetric triage with suspicion of
preterm preeclampsia. In particular, sEng was 10-fold elevated in
women carrying a growth restricted fetus. Furthermore, levels of
sEng were strongly associated with other predictors of preeclamp-
sia-related adverse outcomes similar to sFlt1 and PlGF levels
suggesting common pathogenic pathways leading to preeclampsia
[15]. sEng performed better than current clinical standards
showing high sensitivity and specificity, however it did not
improve the sensitivity of other angiogenic biomarkers (sFlt1/
PlGF ratio) for prediction of adverse maternal and or fetal
outcomes.
Since the conventional clinical parameters lack sufficient
sensitivity and specificity [4,5], it is desirable to identify a
biomarker whose levels bear a close relation to the probability of
developing adverse outcomes in women with suspicion of
preeclampsia. This is akin to the use of troponin for rapid and
reliable diagnosis of acute myocardial infarction in patients
presenting with chest pain [21,22]. Our findings in this prospective
cohort indicate that, in patients first presenting to obstetric triage
elevated sEng levels predict an increased risk of developing
preeclampsia related adverse outcomes including indicated pre-
term delivery. sEng levels provide prognostic information beyond
that supplied by demographic characteristics and clinical presen-
tation. Incorporation of sEng in evaluation of these patients may
allow early identification of patients at risk for adverse outcomes
necessitating timely transfer to a tertiary care center, administra-
tion of betamethasone and also potentially reducing unnecessary
admissions and intervention.
Our findings extend the observation of benefits of measuring
angiogenic factors in patients with suspicion of preeclampsia
[15,17,23]. In comparison to Chaiworapongsa et al or Verlohren
et al [17,23] our study was performed prospectively with analysis
of adverse maternal and perinatal outcomes rather than the
diagnosis of preeclampsia.
These findings also have important implications for the
prediction of preeclampsia. Measurement of antiangiogenic factors
early in pregnancy has limited use for prediction of preeclampsia
with the exception of early-onset preeclampsia [24,25]. It has
therefore been argued that preeclampsia has ‘‘multiple’’ etiologies.
Our previous work [15] and now findings from this article strongly
contradicts that view. Thirty years ago Fisher et al performing
clinical pathological correlation (renal biopsies) studies suggested
the clinical diagnosis of preeclampsia was erroneous in 15% of
nulliparas and nearly 40% of multiparas [26]. Prediction studies,
where the diagnosis of preeclampsia was made by hypertension
and proteinuria were therefore bound to have poor results
whatever marker tested. Our findings when combined with results
from animal studies using sFlt1 and sEng to produce preeclampsia
phenotypes (including endotheliosis) [27,28,29] provide strong
evidence for a single entity that correlates with adverse maternal
and fetal outcomes. It may therefore be worthwhile to re-define
preeclampsia based on a biochemical definition that incorporates
angiogenic factors and then use this as a gold standard for the
prediction studies.
Several limitations of our study must be acknowledged. The
study population was a selected, single center, high-risk group of
women with suspicion of preeclampsia. Although approximately
33% percent of the patients developed an adverse outcome within
2 weeks, the most common adverse outcome was indicated
delivery. Only a small number of patients developed serious
adverse outcomes related to end organ damage such as HELLP
syndrome or acute renal failure. Additionally, we could not
evaluate rare adverse outcomes such as eclampsia or fetal death
because of limited sample size. In our study, we also did not
evaluate subjective components such as experience of the
physicians, individual attitudes and opinions that might have
influenced the decision to delivery. While sFlt1 and PlGF can now
be measured on an automated platform [12], the time required for
measurement of sEng by manual ELISA limits its value as a
diagnostic or prognostic tool for short-term use. Rapid automated
assays that quantify the levels of sEng may need to be developed
but cutoff values must be established that will yield equally
compelling prognostic information.
At preterm gestational ages, safely prolonging pregnancy is
associated with significant fetal benefits, therefore it is of utmost
importance to find a biomarker that is sensitive and reliable so as
not to end pregnancies sooner than necessary. In addition,
healthcare costs associated with unnecessary admissions, multiple
evaluations and the morbidity related to iatrogenic premature
delivery could be reduced by using a test with a high negative
predictive value. This study shows that the sEng levels measured in
triage is a powerful, independent marker of risk in patients with
preeclampsia and related adverse outcomes. Using the current
clinical criteria for diagnosing hypertension and proteinuria along
with sEng levels may facilitate accurate risk assessment of these
patients. Larger studies needs to be done to determine whether use
of angiogenic biomarkers in triage will effectively identify women
at true risk of adverse outcomes and will allow physicians to safely
delay deliveries in patients with favorable angiogenic profiles.
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